Cell Signaling Technology

Product Pathways - Translational Control

CA9 (D47G3) Rabbit mAb #5649

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IHC-P H Endogenous 35-58 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

CA9 (D47G3) Rabbit mAb recognizes endogenous levels of total CA9 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CA9 protein.

Western Blotting

Western Blotting

Western blot analysis of extracts from LN18 and SW620 cells using CA9 (D47G3) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded normal human colon using CA9 (D47G3) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded cell pellets, LN18 (left) or HeLa (right), using CA9 (D47G3) Rabbit mAb.


Background

Carbonic anhydrases (CA) are a family of ancient zinc metalloenzymes found in almost all living organisms. All CA can be divided into 3 distinct classes (α, β, and γ) that evolved independently and have no significant homology in sequence and overall folding. All functional CA catalyze the reversible hydration of CO2 into HCO3- and H+ and contain a zinc atom in the active sites essential for catalysis. There are many isoforms of CA in mammals and they all belong to the α class (1,2).

CA9 is a member of α class and is a plasma membrane protein with the catalytic domain in the extracellular space. Its expression is restricted to very few normal tissues (mainly the gastrointestinal tract) (2). CA9 expression is strongly induced by hypoxia and down-regulated by the wildtype von Hippel–Lindau (VHL) tumor suppressor protein. CA9 expression is increased in many types of tumors, especially solid hypoxic tumors with a poor responsiveness to the conventional radio- and/or chemo-therapies; CA9 is considered to be a tumor hypoxia marker and a promising target for cancer therapeutic intervention (3-5).

  1. Smith, K.S. et al. (1999) Proc Natl Acad Sci USA 96, 15184-9.
  2. Tripp, B.C. et al. (2001) J Biol Chem 276, 48615-8.
  3. Potter, C.P. and Harris, A.L. (2003) Br J Cancer 89, 2-7.
  4. Winum, J.Y. et al. (2009) Anticancer Agents Med Chem 9, 693-702.
  5. De Simone, G. and Supuran, C.T. (2010) Biochim Biophys Acta 1804, 404-9.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products